Acoalan (antithrombin gamma) / Kyowa Kirin - LARVOL DELTA

KW-3357 Study in Patients With Early Onset Severe Preeclampsia (clinicaltrials.gov) - P3 | N=181 | Completed | Sponsor: Kyowa Kirin Co., Ltd. | Recruiting ➔ Completed

Trial completion • Gynecology

KW-3357 Study in Patients With Early Onset Severe Preeclampsia (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: Jan 2023 ➔ Jul 2023 | Trial primary completion date: Jan 2023 ➔ Jun 2023

Trial completion date • Trial primary completion date • Gynecology

KW-3357 Study in Patients With Early Onset Severe Preeclampsia (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: Jun 2022 ➔ Jan 2023 | Trial primary completion date: May 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Gynecology

A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol. (PubMed, Contemp Clin Trials) - "As we have selected a specifically defined target population based on reanalysis of data of a previous plasma-derived antithrombin phase 3 study, the results of our study are expected to provide efficacy and safety data concerning rhAT-gamma treatment in Japanese patients. This study could help identify an effective novel treatment for such patients with early-onset severe preeclampsia for whom appropriate treatment is unavailable."

Clinical • Journal • P3 data • Gynecology • Hypertension

KW-3357 Study in Patients With Early Onset Severe Preeclampsia (clinicaltrials.gov) - P3; N=180; Recruiting; Sponsor: Kyowa Kirin Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

KW-3357 Study in Patients With Early Onset Severe Preeclampsia (clinicaltrials.gov) - P3; N=180; Not yet recruiting; Sponsor: Kyowa Kirin Co., Ltd.

Clinical • New P3 trial